FDA Grants Expedited Approval to Eli Lilly's Foundayo Weight Loss Pill
Federal regulators have given the green light to Eli Lilly's new weight-loss pill, Foundayo, marking it as the second daily oral medication approved to treat obesity and related weight conditions. The U.S. Food and Drug Administration (FDA) authorised the drug, orforglipron, under a new programme designed to significantly reduce drug approval timelines, with the agency reviewing the application in just 50 days.
Pricing and Availability Details for Foundayo
The drug is expected to begin shipping imminently. Eli Lilly has announced that individuals with insurance coverage may access Foundayo for as low as $25 per month using a company discount card. For those paying out-of-pocket, the cost will vary between $149 and $349 monthly, depending on the prescribed dosage. This pricing structure aims to improve affordability compared to many existing treatments.
Clinical Performance and How It Compares to Other Treatments
In a substantial clinical trial involving over 3,000 adults with obesity, participants receiving the highest dose of orforglipron (36 milligrams) experienced an average weight loss of 11.2% of their body weight, equating to approximately 25 pounds over more than 16 months. This contrasts sharply with the placebo group, which saw only a 2.1% reduction, or less than 5 pounds, as reported in the New England Journal of Medicine.
However, both Foundayo and Novo Nordisk's oral Wegovy pill demonstrate less weight loss efficacy on average than leading injectable alternatives. Lilly's own injectable Zepbound typically results in about a 21% average weight loss, while Novo Nordisk's injectable Wegovy averages around 15%.
Convenience and Mechanism of Action
Foundayo operates as a GLP-1 agonist, mimicking a natural hormone that regulates appetite and satiety, similar to widely used injectable medications. As a small-molecule drug, it offers the convenience of being taken once daily without dietary restrictions. This differs from the Wegovy pill, which is a peptide requiring administration with a sip of water on an empty stomach in the morning, followed by a 30-minute wait before eating or drinking.
Additional Health Benefits and Side Effects Profile
The study also noted that users of orforglipron showed improvements in several health metrics, including reductions in waist circumference, blood pressure, triglyceride levels, and cholesterol. The primary side effects were gastrointestinal issues, leading between 5% and 10% of participants in the orforglipron group to discontinue treatment, compared to nearly 3% in the placebo group.
Market Context and Affordability Initiatives
Foundayo joins Novo Nordisk's oral Wegovy, which has spurred over 600,000 prescriptions in the United States since its approval in December. According to a survey by the nonprofit health policy research group KFF, about one in eight people in the U.S. has used injectable GLP-1 drugs, but affordability remains a significant barrier for many due to high costs. The pill from Indianapolis-based Lilly will be included in a Trump administration deal aimed at lowering prices for GLP-1 medications, potentially enhancing access for a broader population.
